Cellectar Biosciences Inc. (CLRB)

2.285 +0.145 (+6.776%)

IEX Real-Time Price

2:01:34 PM EST.

NASDAQ Capital Market : Healthcare

Prev Close 2.14

Price Open 2.13

Volume: 25,455

Avg Volume: 35,979

Market Cap: 10.87M

P/E Ratio -0.01

52 Wk Range 2.02-14.5



CLRB Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
3.02M
419,014
0.74
13.89%

2018-09-28
2.96M
267,317
1.01
9.04%

2018-09-14
2.96M
162,774
1.32
5.50%

2018-08-31
2.96M
161,394
0.98
5.46%




CLRB Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-13
Q3 2018
N/A
0.00 (0)
-1.65
0.00

2018-08-10
Q2 2018
N/A
0.00 (0)
-1.69
0.00

2018-05-11
Q1 2018
N/A
0.00 (0)
-0.21
0.00

2018-05-10
Q1 2018
N/A
0.00 (0)
0.00
0.00

News

FDA grants exemption to Cellectar to import alert for CLR 131 hematology studies (2018-11-12 08:59 SeekingAlpha)

Cellectar Biosciences (NASDAQ: CLRB ) announces that the FDA has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization, the sole supplier of the CLR 131. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the m…

 


Statistics

Shares Outstanding: 4.76M

Top 15 Institution Percent: 13.20

Price To Sales: N/A

Price To Book: 0.76

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -116.83

Return On Equity: -163.95

Profit Margin: N/A

Price History

Beta: 0.43

50-day Moving Avg: 2.58

200-day Moving Avg: 6.67

YTD Change: -84.38

5-day Change: -4.04

1-month Change: -15.08

3-month Change: -10.08

6-month Change: -78.81

1-year Change: -82.09

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Cellectar Biosciences Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.cellectar.com

Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents.